Our top pick for
Annexon, Inc is a biotechnology business based in the US. Annexon shares (ANNX) are listed on the NASDAQ and all prices are listed in US Dollars. Annexon employs 38 staff and has a market cap (total outstanding shares value) of USD$1.1 billion.
|Latest market close||USD$28.98|
|52-week range||USD$15.33 - USD$31.94|
|50-day moving average||USD$25.2962|
|200-day moving average||USD$24.7023|
|Wall St. target price||USD$34.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.2242|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||29.90%|
|1 month (2020-12-16)||12.15%|
|3 months (2020-10-16)||-4.42%|
|6 months (2020-07-12)||N/A|
|1 year (2020-01-12)||N/A|
|2 years (2019-01-12)||N/A|
|3 years (2018-01-12)||N/A|
|5 years (2016-01-12)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-14.22%|
|Return on equity TTM||-23.55%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 572,177 Annexon shares held short by investors – that's known as Annexon's "short interest". This figure is 2.5% down from 586,788 last month.
There are a few different ways that this level of interest in shorting Annexon shares can be evaluated.
Annexon's "short interest ratio" (SIR) is the quantity of Annexon shares currently shorted divided by the average quantity of Annexon shares traded daily (recently around 73544.601542416). Annexon's SIR currently stands at 7.78. In other words for every 100,000 Annexon shares traded daily on the market, roughly 7780 shares are currently held short.
However Annexon's short interest can also be evaluated against the total number of Annexon shares, or, against the total number of tradable Annexon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Annexon's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Annexon shares in existence, roughly 20 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Annexon shares, roughly 17 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Annexon.
Find out more about how you can short Annexon stock.
We're not expecting Annexon to pay a dividend over the next 12 months.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.